This article is more than 5 years old. Information may no longer be current.
Bicruciate TKA offers good outcomes, may not equate to patient satisfaction
Although a bicruciate stabilized knee prosthesis produced good functional and patient-based outcomes at 1 year postoperatively, researchers found the functionality achieved through bicruciate total knee arthroplasty was not equivalent to patient satisfaction.
Ninety-nine patients who underwent total knee arthroplasty (TKA) with the Journey bicruciate stabilized prosthesis (Smith & Nephew) between Aug. 1, 2008, and May 31, 2011, were analyzed prospectively. The researchers collected KOOS, range of motion, Knee Society Knee Score (KS) and Knee Society Knee Function Score (KFS) preoperatively and at 1 year after surgery, and compared pre- and postoperative outcome measures using the Wilcoxon signed-rank test. The researchers also analyzed the correlation between range of motion and patient outcomes using the Spearman coefficient.
Results showed KOOS subscores improved significantly for all patients, with approximately 90% of patients achieving an improvement of at least 10 points in stiffness and other symptoms; 95.4% of patients had improvements in activities of daily living, 90% had improvements in knee-related quality of life and 84.9% saw improvements in sports and recreational activities.
Passive and active range of motion improved from 122.4° and 120.4°, respectively, before surgery to 129.4° and 127.1°, respectively, at follow-up. Additionally, activity and pain subscores were found to have the highest correlation coefficients for range of motion and KOOS, according to the researchers. However, the sport subscore had very little to no correlation.
The researchers observed significant and clinically relevant improvement in Knee Society Score from 112.2 points preoperatively to 174.5 points postoperatively, as well as in and KS (45.6 points vs. 86.8 points) and KFS (66.6 points vs. 87.8 points). – by Monica Jaramillo
Disclosures: The researchers report no relevant financial disclosures.